Skip to content

Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect

Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06396260
Enrollment
50
Registered
2024-05-02
Start date
2024-05-26
Completion date
2026-12-31
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Pseudobulbar Affect

Keywords

Diffusion Kurtosis Imaging, Magnetoencephalography, Connectivity

Brief summary

The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and magnetoencephalography (MEG).

Interventions

Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue

OTHERResting State Magnetoencephalography

Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)

Sponsors

University of Aarhus
CollaboratorOTHER
Aalborg University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Longitudinal imaging study. Baseline acquisition of DKI and resting state MEG of ALS and matched healthy controls. Participants with ALS will be monitored for a period of 6 months for symptoms of PBA. If developed, or not developed after 6 months, follow-up DKI and MEG will be acquired. An additional sub-study will be performed in patients with ALS and newly developed PBA, where resting state MEG will be acquired after at least 7 days of symptomatic treatment independent of the study.

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosed with ALS in the last 6 months according to Gold Coast Criteria

Exclusion criteria

* \- Lack of ability to answer survey through own ability or through a surrogate, for example by hand controlled, eye-controlled computer and/or tablet, or through telephone interview. * Lack of ability to cooperate. * Pregnancy * Drug addiction defined as the non-prescribed use of cannabis, opioids, or other narcotics. * Alcohol addiction defined as over 21 units weekly. * Lesional neurological diseases, such as stroke, tumor or multiple sclerosis * Epilepsy * Neurodegenerative diseases other than ALS * Severe psychiatric disease such as major depression disorder, bipolar disease or schizophrenia * Contraindication for MRI and MEG scan according to hospital guidelines * Severe liver or kidney disease * Dysregulated heart disease * Ongoing treatment with any antidepressants or any antipsychotics at recruitment. * Diagnosed with frontotemporal dementia.

Design outcomes

Primary

MeasureTime frameDescription
Mean kurtosisBaseline measurement and up to 6 month follow-up measurementsA measurement of kurtosis diffusion signal in pseudobulbar affect-affiliated brains areas (prefrontal lobe, pons, cerebellum, motor cortex, temporal lobe) derived from Diffusion kurtosis imaging (DKI)-MRI
Spectral connectivityBaseline measurement and up to 6 month follow-up measurementsEstimation of connectivity (correlation between spikes of activity) between pseudobulbar affect afflilated cortical brain areas (prefrontal cortex, motor cortex, temporal lobe) derived through resting state magnetoencelphalography (MEG)

Countries

Denmark

Contacts

Primary ContactChristian Holm Steenkjær
c.steenkjaer@rn.dk+4597660000
Backup ContactBlicher
Au568472@uni.au.dk+4522144295

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026